forrest innovations

Graematter, Inc.

Graematter provides regulatory intelligence knowledge tools, research services, and expert consulting in the medical products industry. Supported by experienced professionals and a patented, proprietary knowledge management system, you can know what there is to know about medical products - the regulatory path, testing performed, adverse events, the sponsoring company, and the people who played a part in the process. Graematter's Regulatory Intelligence System A comprehensive, patented repository of regulatory information in the medical products industry. Soon to be accessible through subscription. Increase your efficiency and accuracy when developing true Regulatory Intelligence. Founder Graematter was founded by Melissa Walker, MS, RAC, FRAPS. An accomplished senior executive with over 25 years of experience, Melissa has proven expertise in business management, regulatory affairs, quality systems, healthcare compliance, and clinical research, Melissa founded Graematter to ease the burden of collecting and understanding regulatory intelligence.

eurofins discovery

Eurofins Discovery has supported Drug Discovery research for >40 years. Our partners inspire us to innovate in the pursuit of life-changing cures. We provide our experience, depth, and breadth in the form of innovative testing services and product tools that support researchers as they accelerate the discovery and development of candidate molecules. Our global team of dedicated scientists, information analysts, and client support professionals make this mission possible. Our focus drives us to continually expand our portfolio of testing methods, tools, and services to enable real, lasting improvements in human health. Join our dynamic team! View open positions: https://www.eurofinsdiscovery.com/about-us

Exogen Biotechnology, Inc.

Exogen Biotechnology is a Berkeley-based healthcare startup dedicated to quantifying DNA damage and assessing cellular DNA repair capacities. Over 40% of the US population will be diagnosed with cancer and doctors desperately need a way to identify at risk cancer patients and stratify cancer patients for various treatment options. Exogen Bio has developed a technology capable of identifying novel DNA prognostic markers that allows clinicians to better prevent and treat cancer.

ProstaGene

ProstaGene is a biotechnology start up company that is developing technology based on patents of the Founder, Dr. Richard G. Pestell. ProstaGene LLC integrates proprietary molecular diagnostics with novel therapeutic screening and commercial experience in order to develop novel treatments for cancer. The company has developed a diagnostic test that distinguishes benign from malignant prostate cancer with a predictive value of >98% in two retrospective clinical studies. The company has developed a prognostic test that defines a group of patients with poor outcome based on a signature of gene expression in the patients prostate tumor. The company has developed a novel platform for preclinical testing of therapies for metastatic prostate cancer in immune competent mice. The company has identified a therapeutic for metastatic prostate cancer that has shown to be highly effective in preclinical testing.